In recent years, Jiangsu has invested more funds on the transformation of scientific and technological achievements to respond to the needs of people's livelihood by promoting the development of new drugs.
SintilimabInjection, an anti-tumor drugs with independent intellectual property rights independently researched and developed by China, have been on the market for half a year with a retail price of 7838 yuan, which is nearly 60% cheaper than imported drugs.
The success of this drug is inseparable from the efforts of the pharmaceutical team of Innovent Biological Co. Ltd and the support of provincial fund for the transformation of scientific and technological achievements.
At the beginning of 2018, SintilimabInjection entered the third phase of clinical practice and faced a lack of funds. Innovent applied for the provincial science and technology achievements transformation fund and was granted 9 million yuan, making SintilimabInjection the first PD-1 monoclonal antibody to overcome Hodgkin's lymphoma.
The drug has been successfully licensed to Lilly, creating a precedent for Chinese companies to license their own innovative biopharmaceuticals to the world's top 500 pharmaceutical companies.
Zhou Kaisong
Vice President of Process Development, Innovent Biologics, Inc.
A common saying abroad is that
It takes a billion dollars and a decade
to develop a new drug
Developing new drugs costs so much
And this project was developed
with the help of Jiangsu’s special fund
for scientific and technological achievements
With the support from the province's scientific and technological achievements transformation fund, a batch of new drugs have been marketed. In 2018, the State Food and Drug Administration approved a total of 10 domestically produced innovative drugs, 6 of which were from Jiangsu pharmaceutical companies, and 5 were target products supported by the provincial scientific and technological achievements transformation fund project, setting a record high.
By the end of last year, the provincial special fund for the transformation of scientific and technological achievements had successively supported 226 biomedical research projects, with a total investment of 1.8 billion yuan, which has greatly promoted the transformation and industrialization of major original scientific and technological achievements in the field of biomedicine in Jiangsu.
Zhang Haijin Consultant, Office of S&T Commercialization, Jiangsu Provincial Department of Science and Technology
We will improve our core competence
of independent innovation
through the close combination of industry
university and research
and provide strong scientific and technological support
for the construction and high-quality development
of innovative provinces
In addition to biomedicine, the provincial scientific and technological achievements transformation funds have also focused on key industries such as semiconductor chips and advanced materials, as well as technology related to improving people's livelihood. Up to now, the provincial scientific and technological achievements transformation funds have supported 1,884 projects, and invested 66.5 billion yuan, which has in turned encouraged enterprises to increase investment of 183 billion yuan, and achieve sales revenue of nearly one trillion yuan.
(source:ourjiangsu.com)